Skip to content
TrialScanner

NCT01679990

Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)

Phase 2CompletedPLURLead

Registry record

Lead sponsor
Pluristem Ltd.
Conditions
Intermittent Claudication; Peripheral Artery Disease
Primary completion
Mar 29, 2018Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT01679990 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT01679990: Safety and Efficacy of... | TrialScanner